Othman Ahmed A, Newman Amy Hauck, Eddington Natalie D
Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Baltimore, MD 21201, USA.
J Pharmacol Exp Ther. 2007 Aug;322(2):760-9. doi: 10.1124/jpet.107.123315. Epub 2007 May 22.
Previous studies indicated that the chloro-benztropine analogs differed significantly in their cocaine-like activity, which was not expected based on the similarity in their in vitro binding affinity and functional potency at the dopamine transporter (DAT). The present study was designed to extend the understanding of the involvement of both pharmacokinetic and pharmacodynamic factors in mediating the behavioral differences among these analogs. The pharmacokinetics of 3'-chloro-3alpha-(diphenylmethoxy)tropane (3'-Cl BZT), the analog showing a cocaine-like behavioral profile in rodents, was compared with previously reported pharmacokinetic characteristics of cocaine and 4',4''-dichloro-3alpha-(diphenylmethoxy)tropane (4',4''-diCl BZT), an analog totally devoid of cocaine-like actions. Microdialysis studies in rats were conducted to determine whether 3'-Cl and 4',4''-diCl BZT differed significantly in their effect on nucleus accumbens extracellular dopamine levels, with cocaine serving as a reference. A mechanistic model based on DAT association/dissociation kinetics was used to describe the time delay between the plasma concentrations of the chloro-analogs and their dopaminergic effects. 3'-Cl BZT had plasma elimination half-life of 1.9 h versus 0.5 and 21.1 h for cocaine and 4',4''-diCl BZT, respectively. 4',4''-diCl BZT increased the DA levels at a slower rate and to a significantly lower extent relative to 3'-Cl BZT that were, in turn, lower than cocaine. The duration of dopamine elevation was as follows: 4',4''-diCl BZT > 3'-Cl BZT > cocaine. The model indicated faster association and dissociation with DAT for 3'-Cl BZT relative to 4',4''-diCl BZT. The present results indicate that behavioral differences among the chloro-analogs may be explainable based on both the dopamine and rate hypotheses of drug abuse.
先前的研究表明,氯苯托品类似物在其可卡因样活性方面存在显著差异,基于它们在体外对多巴胺转运体(DAT)的结合亲和力和功能效价的相似性,这是出乎意料的。本研究旨在进一步了解药代动力学和药效学因素在介导这些类似物行为差异中的作用。将在啮齿动物中表现出可卡因样行为特征的类似物3'-氯-3α-(二苯基甲氧基)托烷(3'-Cl BZT)的药代动力学与先前报道的可卡因和4',4''-二氯-3α-(二苯基甲氧基)托烷(4',4''-二氯BZT)的药代动力学特征进行比较,4',4''-二氯BZT是一种完全没有可卡因样作用的类似物。在大鼠中进行微透析研究,以确定3'-Cl BZT和4',4''-二氯BZT对伏隔核细胞外多巴胺水平的影响是否存在显著差异,以可卡因作为对照。基于DAT结合/解离动力学的机制模型用于描述氯类似物血浆浓度与其多巴胺能效应之间的时间延迟。3'-Cl BZT的血浆消除半衰期为1.9小时,而可卡因和4',4''-二氯BZT的血浆消除半衰期分别为0.5小时和21.1小时。与3'-Cl BZT相比,4',4''-二氯BZT升高多巴胺水平的速率较慢,程度也显著较低,而3'-Cl BZT又低于可卡因。多巴胺升高的持续时间如下:4',4''-二氯BZT>3'-Cl BZT>可卡因。该模型表明,相对于4',4''-二氯BZT,3'-Cl BZT与DAT的结合和解离更快。目前的结果表明,基于药物滥用的多巴胺和速率假说,氯类似物之间的行为差异可能是可以解释的。